130 related articles for article (PubMed ID: 37619788)
1. Pneumonitis Rates Before and After Adoption of Immunotherapy Consolidation in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Concurrent Chemoradiation.
Yegya-Raman N; Friedes C; Lee SH; Iocolano M; Duan L; Wang X; Li B; Aggarwal C; Cohen RB; Su W; Doucette A; Levin WP; Cengel KA; DiBardino D; Teo BK; O'Reilly SE; Sun L; Bradley JD; Xiao Y; Langer CJ; Feigenberg SJ
Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1445-1454. PubMed ID: 37619788
[TBL] [Abstract][Full Text] [Related]
2. Pneumonitis After Concurrent Chemoradiation and Immune Checkpoint Inhibition in Patients with Locally Advanced Non-small Cell Lung Cancer.
Altan M; Soto F; Xu T; Wilson N; Franco-Vega MC; Simbaqueba Clavijo CA; Shannon VR; Faiz SA; Gandhi S; Lin SH; Lopez P; Zhong L; Akhmedzhanov F; Godoy MCB; Shroff GS; Wu J; Khawaja F; Kim ST; Naing A; Heymach JV; Daniel-Macdougall C; Liao Z; Sheshadri A
Clin Oncol (R Coll Radiol); 2023 Oct; 35(10):630-639. PubMed ID: 37507279
[TBL] [Abstract][Full Text] [Related]
3. Cardiac radiation dose is associated with inferior survival but not cardiac events in patients with locally advanced non-small cell lung cancer in the era of immune checkpoint inhibitor consolidation.
Yegya-Raman N; Ho Lee S; Friedes C; Wang X; Iocolano M; Kegelman TP; Duan L; Li B; Berlin E; Kim KN; Doucette A; Denduluri S; Levin WP; Cengel KA; Cohen RB; Langer CJ; Kevin Teo BK; Zou W; O'Quinn RP; Deasy JO; Bradley JD; Sun L; Ky B; Xiao Y; Feigenberg SJ
Radiother Oncol; 2024 Jan; 190():110005. PubMed ID: 37972736
[TBL] [Abstract][Full Text] [Related]
4. Radiation pneumonitis in patients with non-small-cell lung cancer receiving chemoradiotherapy and an immune checkpoint inhibitor: a retrospective study.
Jang JY; Kim SS; Song SY; Kim YJ; Kim SW; Choi EK
Radiat Oncol; 2021 Dec; 16(1):231. PubMed ID: 34863244
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive Pneumonitis Profile of Thoracic Radiotherapy Followed by Immune Checkpoint Inhibitor and Risk Factors for Radiation Recall Pneumonitis in Lung Cancer.
Lu X; Wang J; Zhang T; Zhou Z; Deng L; Wang X; Wang W; Liu W; Tang W; Wang Z; Wang J; Jiang W; Bi N; Wang L
Front Immunol; 2022; 13():918787. PubMed ID: 35795657
[TBL] [Abstract][Full Text] [Related]
6. Dose-Volume Predictors of Radiation Pneumonitis After Thoracic Hypofractionated Radiation Therapy.
Sasse A; Oh P; Saeed N; Yang DX; Hayman TJ; Knowlton CA; Peters GW; Campbell A; Laird J; Housri N; Park HS
Pract Radiat Oncol; 2024; 14(2):e97-e104. PubMed ID: 37984711
[TBL] [Abstract][Full Text] [Related]
7. Decreased risk of radiation pneumonitis with incidental concurrent use of angiotensin-converting enzyme inhibitors and thoracic radiation therapy.
Kharofa J; Cohen EP; Tomic R; Xiang Q; Gore E
Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):238-43. PubMed ID: 22300564
[TBL] [Abstract][Full Text] [Related]
8. Dose-volume analysis of radiation pneumonitis in non-small-cell lung cancer patients treated with concurrent cisplatinum and etoposide with or without consolidation docetaxel.
Barriger RB; Fakiris AJ; Hanna N; Yu M; Mantravadi P; McGarry RC
Int J Radiat Oncol Biol Phys; 2010 Dec; 78(5):1381-6. PubMed ID: 20231061
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of immune checkpoint inhibitor consolidation after chemoradiation in patients of Asian ethnicity with unresectable stage III non-small cell lung cancer: Chinese multicenter report and literature review.
Zhang T; Xu K; Bi N; Zhang L; Jiang W; Liang J; Deng L; Wang X; Wang J; Wang J; Wang L
Thorac Cancer; 2020 Oct; 11(10):2916-2923. PubMed ID: 32833338
[TBL] [Abstract][Full Text] [Related]
10. Incidence and Risk Factors of Symptomatic Radiation Pneumonitis in Non-Small-Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy and Consolidation Durvalumab.
Shintani T; Kishi N; Matsuo Y; Ogura M; Mitsuyoshi T; Araki N; Fujii K; Okumura S; Nakamatsu K; Kishi T; Atsuta T; Sakamoto T; Narabayashi M; Ishida Y; Sakamoto M; Fujishiro S; Katagiri T; Kim YH; Mizowaki T
Clin Lung Cancer; 2021 Sep; 22(5):401-410. PubMed ID: 33678582
[TBL] [Abstract][Full Text] [Related]
11. Dosimetric predictors of pneumonitis in locally advanced non-small cell lung cancer patients treated with chemoradiation followed by durvalumab.
Gao RW; Day CN; Yu NY; Bush A; Amundson AC; Prodduturvar P; Majeed U; Butts E; Oliver T; Schwecke AJ; Moffett JN; Routman DM; Breen WG; Potter AL; Rivera-Concepcion J; Hoppe BS; Schild SE; Sio TT; Lou Y; Ernani V; Ko S; Olivier KR; Merrell KW; Garces YI; Manochakian R; Harmsen WS; Leventakos K; Owen D
Lung Cancer; 2022 Aug; 170():58-64. PubMed ID: 35716632
[TBL] [Abstract][Full Text] [Related]
12. Symptomatic Radiation Pneumonitis in NSCLC Patients Receiving EGFR-TKIs and Concurrent Once-daily Thoracic Radiotherapy: Predicting the Value of Clinical and Dose-volume Histogram Parameters.
Yang X; Mei T; Yu M; Gong Y
Zhongguo Fei Ai Za Zhi; 2022 Jun; 25(6):409-419. PubMed ID: 35747920
[TBL] [Abstract][Full Text] [Related]
13. Radiation and immune checkpoint inhibitor-mediated pneumonitis risk stratification in patients with locally advanced non-small cell lung cancer: role of functional lung radiomics?
Thomas HMT; Hippe DS; Forouzannezhad P; Sasidharan BK; Kinahan PE; Miyaoka RS; Vesselle HJ; Rengan R; Zeng J; Bowen SR
Discov Oncol; 2022 Sep; 13(1):85. PubMed ID: 36048266
[TBL] [Abstract][Full Text] [Related]
14. Independent association of metabolic tumor response on FDG-PET with pulmonary toxicity following risk-adaptive chemoradiation for unresectable non-small cell lung cancer: Inherent radiosensitivity or immune response?
Gates EDH; Hippe DS; Vesselle HJ; Zeng J; Bowen SR
Radiother Oncol; 2023 Aug; 185():109720. PubMed ID: 37244360
[TBL] [Abstract][Full Text] [Related]
15. A comparison of the incidence of ≥ grade 2 radiation pneumonitis between intensity-modulated radiotherapy and three-dimensional conformal radiotherapy in patients with unresectable non-small cell lung cancer treated with durvalumab after concurrent chemoradiotherapy.
Masuo M; Shinohara E; Kitano M; Maruta R; Chonabayashi S; Endo S; Matumoto S; Nishiyama N; Machitori Y; Kobayashi M
Jpn J Clin Oncol; 2024 Mar; 54(3):312-318. PubMed ID: 38010609
[TBL] [Abstract][Full Text] [Related]
16. Adding ipsilateral V20 and V30 to conventional dosimetric constraints predicts radiation pneumonitis in stage IIIA-B NSCLC treated with combined-modality therapy.
Ramella S; Trodella L; Mineo TC; Pompeo E; Stimato G; Gaudino D; Valentini V; Cellini F; Ciresa M; Fiore M; Piermattei A; Russo P; Cesario A; D'Angelillo RM
Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):110-5. PubMed ID: 19619955
[TBL] [Abstract][Full Text] [Related]
17. Utilization and Factors Precluding Receipt of Checkpoint Inhibitor Consolidation for Stage III NSCLC in a Large US Academic Health System.
Yegya-Raman N; Friedes C; Sun L; Iocolano M; Kim KN; Doucette A; Cohen RB; Robinson KW; Levin WP; Cengel KA; Lally B; Agarwal M; D'Avella CA; Marmarelis ME; Kosteva JA; Singh AP; Ciunci CA; Aggarwal C; Berman AT; Langer CJ; Feigenberg SJ
Clin Lung Cancer; 2023 Jul; 24(5):474-482. PubMed ID: 37076396
[TBL] [Abstract][Full Text] [Related]
18. Radiation pneumonitis after definitive concurrent chemoradiotherapy with cisplatin/docetaxel for non-small cell lung cancer: Analysis of dose-volume parameters.
Katsui K; Ogata T; Watanabe K; Katayama N; Kuroda M; Kiura K; Hiraki T; Maeda Y; Toyooka S; Kanazawa S
Cancer Med; 2020 Jul; 9(13):4540-4549. PubMed ID: 32364685
[TBL] [Abstract][Full Text] [Related]
19. Potential benefits of volumetric modulated arc therapy to reduce the incidence of ≥ grade 2 radiation pneumonitis in radiotherapy for locally advanced non-small cell lung cancer patients.
Imano N; Kimura T; Kawahara D; Nishioka R; Fukumoto W; Kawano R; Kubo K; Katsuta T; Takeuchi Y; Nishibuchi I; Murakami Y; Horimasu Y; Masuda T; Fujitaka K; Hattori N; Nagata Y
Jpn J Clin Oncol; 2021 Dec; 51(12):1729-1735. PubMed ID: 34625805
[TBL] [Abstract][Full Text] [Related]
20. Predictors of Pneumonitis in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Definitive Chemoradiation Followed by Consolidative Durvalumab.
Diamond BH; Belani N; Masel R; DeCarli K; DiPetrillo T; Hepel JT; Azzoli CG; Khurshid H; Abbas A; Koffer PP
Adv Radiat Oncol; 2023; 8(2):101130. PubMed ID: 36845618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
